Cancer Research · us
Making Prostate Cancer Sensitive to Drugs Again: Study Finds Clues to How Transfer RNA Regulates Cell Identity
Cancer cells changing identity and escaping their dependence on androgen signaling is one reason advanced prostate cancer is difficult to treat. A new study found that restoring a specific transfer RNA can restore treatment sensitivity in experimental cells; how to turn this pathway into a safe and effective therapy remains unanswered.
One challenge in treating prostate cancer is that cancer cells sometimes change how they survive. Tumors that initially rely on androgen receptor signaling may gradually escape this dependence, making drugs that target the receptor ineffective. A study published in *Nature* on October 7 traced this transition to a small RNA involved in protein production and found clues to making experimental cells sensitive to treatment again.
A team from the University of Chicago, Fred Hutch Cancer Center, and other institutions focused on a transfer RNA called tRNA1Arg(UCU). Transfer RNAs typically carry amino acids during protein synthesis; this study shows that changes in the abundance of a specific type may also affect the identity cancer cells maintain and whether they continue to depend on the androgen receptor.
The research included prostate cancer cell lines, mouse models, and patient tumor samples. According to Fred Hutch, the team observed a consistent trend across these systems: cancer cells that depended on the androgen receptor had higher levels of this transfer RNA, while tumors with reduced receptor dependence and treatment resistance had lower levels. This prompted the researchers to ask whether the decline in RNA merely accompanied changes in the tumors or helped drive them.
Manipulating RNA levels in cells provided more direct evidence. According to the University of Chicago, reducing tRNA1Arg(UCU) also lowered androgen receptor levels in cancer cells; restoring this RNA restored receptor activity and treatment sensitivity. This supports its involvement in regulating cell state, but the restoration observed so far comes from experimental systems and cannot be taken as evidence of therapeutic efficacy in patients.
The team also linked this pathway to SMARCC2, a protein involved in chromatin remodeling that helps adjust how DNA is organized. When levels of the specific transfer RNA fell, SMARCC2 production also declined, making cancer cells more likely to shift away from their original state. In experiments, restoring SMARCC2 likewise made cells sensitive to treatment again, providing a clue to the downstream mechanism through which RNA affects cell identity.
These findings suggest two research directions: whether transfer RNA levels can be used to identify tumors that are changing state, and whether modulating this pathway can restore the effects of existing drugs. Fred Hutch said researchers are exploring biomarker and therapeutic applications; the University of Chicago proposed possible strategies such as synthetic transfer RNA mimics or small molecules that increase its production. All remain concepts awaiting development.
Several key questions remain in moving from cell experiments to treatment: how to deliver the intervention into tumors, how long the restored sensitivity can last, and whether intervening in pathways related to protein synthesis would affect normal cells. Patient samples support the findings’ relevance to the disease, but have not yet demonstrated that restoring the RNA can improve patients’ treatment responses or survival. The advance in this study is that it links part of the mechanism of drug resistance to a potentially modifiable RNA layer, providing a concrete direction for further validation.